Stalevo (levodopa;carbidopa;entacapone)
- Region
- 🇪🇺 EU
- Active substance
- levodopa;carbidopa;entacapone
- Company
- Orion Corporation
- Status
- Authorised
- Therapeutic area
- Parkinson Disease
- EU approval
- Fri 17 Oct 2003
- Application
- EMEA/H/C/000511
- ATC
- N04BA03
- Official record
- www.ema.europa.eu
Indication
Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz) Authorised · Orion Corporation
- 🇪🇺 Levodopa/Carbidopa/Entacapone Orion Authorised · Orion Corporation
Follow Stalevo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.